Purpose of the Study

 Helios Clinical Research is conducting a clinical research study related to common EGFR-mutated locally advanced or metastatic non-small cell lung cancer. The purpose of this study is to assess the antitumor activity of amivantamab and lazertinib, and amivantamab and chemotherapy, in participants with EGFRm NSCLC. The research team is seeking adults who meet the eligibility criteria, including being ≥18 years of age at the time of informed consent, to learn whether they may qualify. 

Study Requirements

  • Are ≥18 years of age at the time of informed consent. 
  • Have histologically or cytologically confirmed advanced or metastatic NSCLC that is not amenable to curative intent therapy.
  •  Have at least 1 measurable lesion, according to RECIST v1.1. 

Potential Benefits of Participation

Maginfying

Access to new treatments that are
not yet available to the general public.

Hand Heart

Personalized medical attention from
leading healthcare professionals.

Helios

Compensation provided to qualified participants

Study Locations

These studies are currently enrolling at the following sites:

The Oncology Institute Powered by Helios - Fort Lauderdale, FL
The Oncology Institute Powered by Helios - Long Beach, CA
The Oncology Institute Powered by Helios - Whittier, CA
The Oncology Institute Powered by Helios - Santa Ana, CA
The Oncology Institute Powered by Helios - San Gabriel, CA

About Helios Clinical

Helios Clinical is dedicated to advancing medical research through innovative clinical trials.
Our mission is to discover new ways to improve patient health and outcomes.
We collaborate with leading healthcare professionals and scientists
to ensure the highest standards of research and care for our participants.